SCHEMBL20195362

SCHEMBL20195362

c1ccc(-c2nc(-c3ccccc3)nc(-c3ccc(-c4cccc5cc(-c6cc(-c7ccccn7)cc(-c7ccccn7)c6)ccc45)cc3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.41
KDM4E B2RXH2 4/20 0.41
HSD17B10 Q99714 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
TP53 P04637 4/20 0.41
NPC1 O15118 4/20 0.41
HPGD P15428 4/20 0.41
MAPK1 P28482 2/20 0.41
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
GRM5 P41594 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
TGFBR1 P36897 1/20 0.39
RAB9A P51151 4/20 0.39
LMNA P02545 3/20 0.39
TSHR P16473 3/20 0.39
PKM P14618 3/20 0.39
KLF5 Q13887 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21098931 0.95 SMN1; SMN2 (0.41) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL17829267 0.94 ALDH1A1 (0.42) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL17829282 0.94 ALDH1A1 (0.42) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL17598658 0.92 SMN1; SMN2 (0.43) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL21099081 0.90 TNF (0.41) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL23953185 0.90 KDM4E (0.42) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL17598677 0.88 SMN1; SMN2 (0.45) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL20195361 0.88 KDM4E (0.44) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL17413704 0.87 KDM4E (0.44) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT
SCHEMBL17343268 0.87 KDM4E (0.51) SMN1; SMN2KDM4EHSD17B10ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327008-B1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME LG CHEMICAL LTD (KR) 2021-10-27 EP disclosed
US-10323006-B2 Heterocyclic compound and organic light emitting element using same LG CHEM, LTD. (KR) 2019-06-18 US disclosed
EP-3327008-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT USING SAME LG Chem, Ltd. (KR) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10323006-B2 Heterocyclic compound and organic light emitting element using same CRY1, CRY2, NR2E3 SMN1; SMN2 3226/4885KDM4E 1017/4885HSD17B10 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.